Information Provided By: 
Fly News Breaks for May 10, 2017
TSRO
May 10, 2017 | 07:14 EDT
After Tesaro posted a wider than expected Q1 loss, Jefferies analyst Eun Yang says she views meaningful upside to the shares as limited in the absence of potential buyout. With three PARP inhibitors on the U.S. market with similar efficacy profiles, the ovarian cancer market is highly competitive, Yang tells investors in a post-earnings research note. She keeps a Hold rating on Tesaro.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
